Animal Health
Biotech
GMP
Intellectual Property
Legal
Management Skills
Medical Devices
Pharma online
Pharmaceutical
Support Staff

Sponsoring & Exhibiting

For sponsorship and exhibition opportunities at Management Forum events click here

Event Management

To find out about event management click here

Speaking Opportunities

Speaking opportunities are available on selected Management Forum events, please contact us for further information

Management Forum Brochure

Download our catalogue here

Medical Devices

EC Medical Devices Vigilance System and Post Marketing Surveillance

30-31 Jan 2018

GBP EUR USD
Standard 1499 2099 2338
Early 1299 1819 2026
Excluding VAT @ 20.00%

Book by 22 Dec to get the early booking price shown above.

Venue: Rembrandt Hotel, London

Enrol now

Select currency when checking out

Bespoke training

We can customise this course to meet the requirements of your organisation.

Learn more

Course Overview

While the pre-market approval process has been delegated by most of the Competent Authorities to the private sector, Competent Authorities have kept the responsibility for the surveillance of their market. Because of this situation there is transfer of resource and energy to the monitoring of markets including the vigilance system within each Member State. The evaluation of incidents notified by manufacturers and users represents a key source of information for authorities, combined with sophisticated exchange of information between EU Member States, and with other countries like USA, Japan, Canada or Australia, provides a unique insight into the performance of devices in the post production phase.

Full compliance with the vigilance requirements laid down in Article 10 of Directive 93/42/EC is justified by the manufacturers’ legal obligations, risks associated to litigation and increasing scrutiny of Member States, but mainly by the ultimate objective of providing safe devices to patients. It is essential that manufacturers ensure compliance with these requirements.

This conference will provide practical advice on how to comply with these requirements including how to handle adverse event reporting during medical device clinical studies.

Why you should attend

This conference provides a unique opportunity to meet Competent Authorities, Notified Bodies, Lawyers, consultants and manufacturers to understand and discuss the regulatory and legal requirements with respect to Post Marketing Surveillance including Vigilance.

Who should attend

This conference will be of importance to all those involved in the Medical Device Industry in the following departments; Manufacturing, Research and Development, Registration, Product Safety, Adverse Event Monitoring, Regulatory Affairs, Distribution and all those interested in Medical Device Vigilance in the European Community.

Programme Day One

09.30 Chairman’s Welcome and Introduction Roland Gérard

09.40 Introduction to Post Marketing Surveillance Tony Sant

10.20 In Depth Review of the EU Vigilance Process Roland Gérard

11.00 Discussion

11.10 Coffee

11.30 Application of the Reporting Rules

  • Case Studies
    Group Exercise led by Roland Gerard, Tony Sant and Dr Ekkehard Stösslein

12.20 Discussion

12.30 Lunch

13.30 Legal Aspects of Manufacturers Reporting Obligations

  • Main EU markets and US FDA
    Dr Grant Castle

14.30 Legal Aspects of FSCA

  • Product liability issues that might arise if one fails to take appropriate corrective action
  • The powers regulators have to act against products
    Dr Grant Castle

15.30 Discussion

15.40 Tea

16.00 Field Safety Corrective Actions (FSCA): Expectations from Authorities
Dr Ekkehard Stösslein

16.30 Handling of Field Safety Corrective Actions (FSCA) – Industry Perspective
Roland Gérard

17.15 Discussion

17.30 End of Day One

Programme Day Two

09.00 Post Marketing Surveillance: an integral part of the QA system

  • Critical elements of risk Management, CAPA, PMS, Field Action SOPs
    Susanna Faria

09.30 Role of Notified Bodies in vigilance
Susanna Faria

10.20 Germany and vigilance:BfArM

  • Organisation
  • Handling of vigilance reports • National guidelines
  • Sharing of experiences
    Dr Ekkehard Stössleinn

10.45 Discussion

11.00 Refreshments

11.15 UK and vigilance: MHRA

  • Organisation
  • Handling of vigilance reports • National guidelines
  • Sharing of experiences
    Tony Sant

12.00 Medical device regulation changes affecting PMS
Dr Ekkehard Stössleinn

13.00 Lunch

14.00 Revision of vigilance guidelines:

  • Trending and FSN format
    Tony Sant

14.45 Refreshments

15.00 PMS and adverse event reporting during medical device studies
Janette Benaddi

16.00 Discussion and closing remarks

16.15 Close of conference

You may also be interested in

Adverse Event Management During Medical Device Clinical Studies on 28 January 2016

Presenters

Janette Benaddi

Janette Benaddi is an Independent Consultant and previously Director of Clinical & Consulting Europe for NAMSA. NAMSA is a global Medical Research Organization offering a breadth of services form preclinical to post market activities throughout the medical device product development cycle.

She has over 20 years’ experience of managing pre and post market clinical studies in both devices and pharmaceuticals. She has worked with several multinational organizations in various clinical, regulatory and marketing roles. She has extensive experience of conducting clinical studies with medical device products as well as regulatory expertise for CE marking of devices.

She is a registered nurse, has a BSc in Management studies, a Diploma in Company Direction and a Diploma in Management studies, she holds a teaching certificate and is a Chartered Scientist and Chartered Director. Janette sits on several committees in the device community and industry and has been an instrumental advocate of improving and advancing medical device research in the UK. She has published several articles relating to medical device regulation and clinical studies.

Ekkehard Stosslein

Dr. Ekkehard Stösslein is the Deputy Head of the Medical Devices Department and Head of the Active Medical Devices and IVD Section at the Federal Institute for Drugs and Medical Devices (BfArM) in Bonn/Germany. Prior to the constitution of BfArM in July 1994 he was with the former Bundesgesundheitsamt (Federal Health Department), organizing the practical implementation of the Active Implantable Medical Device Directive in Germany. He is a member of the Medical Devices Experts Group on Vigilance and was a member of the Study Group II of the Global Harmonisation Task Force.

Grant Castle

Grant Castle is a Partner in the London office of Covington & Burling, practicing in food and drug regulatory law, with an emphasis on pharmaceutical and medical device regulation and associated data protection laws.
He has assisted clients with applications for the centralised approval of medicinal products, EC orphan drug designation, and with regulatory issues in the national approval process for medicines, including the EC mutual recognition procedure. He has participated in formal and informal good manufacturing practices (GMP), good clinical practices (GCP), advertising, borderline, drug safety and pharmacovigilance proceedings before the European Medicines Agency (EMEA), national authorities, courts and self-regulatory bodies. His litigation experience includes judicial review proceedings in the UK and EC courts, including the first challenge to a Community marketing authorisation for a medicinal product in the European Court of First Instance.
He received a BSc in Chemistry with first class honours from Imperial College of Science, Technology and Medicine in London in 1991 and a PhD in Organic Chemistry from Trinity College, University of Cambridge in 1994.
He has published extensively in the legal literature and has made several contributions to the technical literature in chemistry. He speaks and lectures frequently on pharmaceutical, medical device, data privacy and borderline products regulation at the Universities of Surrey and Wales, University of Cranfield, and business and professional groups in Europe and the U.S.

Tony Sant

Tony Sant is a Group Manager for MHRA’s Adverse Incident Centre and Biosciences and Implants specialist unit. He graduated in Physics at Imperial College, London and went on to obtain an MSc in Medical Physics and Medical Electronics at St Bartholomew’s Hospital. He joined one of MHRA’s precursors in 1985 from Medeci Medical Ltd. where he was employed as a medical electronics test engineer. At MHRA he has gained experience in: adverse incident investigation and incident systems development, quality systems auditing; medical device research and development, medical device evaluation project management, and general management of staff and other resources.
He has been instrumental in MHRA introducing and developing on-line reporting for users and manufacturers and was also closely involved in the development of SABRE MHRA’s Haemovigilance reporting system in 2005. He has been an active European representative of Study Group 2 (Adverse Events and Postmarket Surveillance) of the Global Harmonisation Task Force, where he led on guidance documents for electronic reporting of adverse incidents. He is an active member of the European Medical Device Experts Group on Vigilance and its sub-groups which recently revised the EU’s vigilance guidance and which currently are developing proposals for future comitology and recasting of EU medical device vigilance.

Roland Gerard

Roland Gerard, Independent Consultant and previously Vice President Regulatory and Quality Affairs International Division, St Jude Medical, where he was responsible for quality and regulatory compliance including vigilance within the International product division of St. Jude Medical. He was a member of the Global Harmonisation Task Force Steering Committee and a member of Study Group II on Vigilance and Post Marketing Surveillance representing EUCOMED. He was President of IAPM (International Association of Prosthesis Manufacturers) and past Chairman of the IAPM Technical and Legal Committee. He is currently chairman of the EUCOMED Regulatory Affair Committee (RAC).

Susana Faria

Susana da Cruz Faria is a Product Technical Specialist / Scheme Manager of BSI Group, part of the Orthopaedic & Dental technical team. She joined BSI, after 12 years’ experience working for medical device manufacturers including Zimmer (Switzerland), Philips (Netherlands) and Ceramed (Portugal). In industry, she worked with joint replacement and spinal implants, as well coatings for orthopaedic implants and instruments. She has a Masters degree in Materials Engineering.

Previous customers include...

  • Abbott Spine
  • Alcon-Couvreur
  • Allergan UK Limited
  • BECKMAN COULTER
  • Becton Dickinson B.V.
  • Becton Dickinson İth. İhr. Ltd. Şti.
  • Bio-Technology General (Israel) Ltd
  • bioMerieux SA
  • Colgate-Palmolive R&D
  • Contura International A/S
  • Dada Consultancy BV
  • Dentsplysirona
  • Dr Max Pharma Ltd
  • Elekta Oncology Systems Ltd
  • European PharmInvent Services s.r.o.
  • Gambro Lundia AB
  • Kimberly-Clark Corporation
  • Korea Health Industry Development Institute (KHIDI)
  • Lifescan
  • Magstim
  • Medix Biochemica
  • Oxoid Thermo Fisher Scientific Ltd
  • Pharmatek Consultancy Services
  • QUINTILES CONSULTING - MTC
  • Sinclair Pharma SRL
  • SIRO Clinpharm Germany GmbH
  • SSL INTERNATIONAL
  • Thermo Fisher Scientific Oy
  • Valtech Cardio
  • Wright Medical Technology Inc